Intuitive Surgical Q2: The Market Is Missing The Bigger Picture
Intuitive Surgical, Inc. Q2 beat: 20% da Vinci procedure growth and 70% gross margin. Click for this updated look at ISRG following the selloff after its earnings.
Archived explainer. For the current picture see today's ISRG page.
INTUITIVE SURGICAL I (ISRG) is down -14.15% in the latest session. Our newswire has captured 30 stories on ISRG across 17 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Intuitive Surgical (ISRG) stock fell 14.15% to $345.42 on July 17, marking its largest one-day decline in recent history. The drop followed the company’s second-quarter earnings report, which, despite beating revenue and earnings estimates, included weaker-than-expected guidance on U.S. procedure growth for its da Vinci surgical systems. Analysts and investors reacted to the muted outlook by cutting price targets, triggering a sharp sell-off.
Intuitive Surgical reported Q2 results that exceeded revenue and EPS expectations, with 21.4% year-over-year revenue growth and 70% gross margin. However, the company’s forward guidance for full-year da Vinci procedure growth of 13.5% to 15.5% fell short of investor expectations. The slowdown in U.S. procedure growth, a key driver of long-term revenue, raised concerns about the company’s ability to sustain high growth rates. In response, several Wall Street analysts cut price targets. Citi lowered its price target to $500 from $590, while Piper Sandler and Raymond James also reduced their estimates. The stock opened with an 11.2% gap down at $357.20 and continued to fall throughout the session, reaching a low of $344.55.
The stock has fallen 15.3% over the past eight sessions, closing at $354.69 after opening the week at $418.83. Trading volume surged to 9.1 million shares, or 4.1 times the 3-month average, indicating heightened investor activity. The stock hit a 52-week low of $344.55 during the session, marking the 21st such low of the year. Meanwhile, insider transactions show six sales totaling $2.8 million in the last 90 days, with no buy activity reported. Congressional trades also show recent selling by Rep. Ro Khanna, though no single transaction exceeded $50,000.
The stock is set to continue under pressure as analysts refine their expectations and investors assess the long-term implications of slower U.S. procedure growth. Coverage from 30 stories across 17 sources in the last 36 hours indicates broad market attention, with further price target adjustments likely.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Intuitive Surgical, Inc. Q2 beat: 20% da Vinci procedure growth and 70% gross margin. Click for this updated look at ISRG following the selloff after its earnings.
Intuitive Surgical tumbles 14% after the second quarter's revenue print and forward guidance came in below expectations, Jefferies analysts wrote. The medical robotics company maintained its growth forecast for the use of its Da Vinci robot, disappointing investors who expected the company to raise its estimate, the analysts said. Moreover, growth in robot-assisted surgeries in the U.S. is slowing, as patients put off non-emergency surgeries following changes in insurance coverage, they said…
Stock indexes in the U.S. closed down Friday with the NASDAQ Composite Index declining 1.40%. Meanwhile, the S&P 500 Index declined 1.01%, and the Dow fell 0.77%.
Intuitive Surgical stock sinks as muted guidance triggers a wave of Wall Street price cuts. But ISRG shares may still be worth buying on the dip.
Find insight on Eli Lilly, GSK, Intuitive Surgical and more in the latest Market Talks covering the Health Care sector.
Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second...
According to TheFly, Citi lowered its price target to $500 from $590 and keeps a ‘Buy’ rating.
Intuitive Surgical (ISRG) stock falls as soft U.S. growth in the company's da Vinci surgical systems overshadows better-than-expected Q2 results. Readmore here.
More on ISRG: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ISRG move explainers: 2026-07-20 · 2026-07-17 · 2026-07-16 · 2026-07-14